InvestorsHub Logo
Followers 130
Posts 14996
Boards Moderated 1
Alias Born 06/04/2018

Re: None

Sunday, 09/29/2019 9:10:29 AM

Sunday, September 29, 2019 9:10:29 AM

Post# of 284
News: $SGEN Initial Results from MOUNTAINEER Trial Show Antitumor Activity of Tucatinib Combination in HER2-Positive Metastatic Colorectal Cancer

- First Presentation of Tucatinib With Trastuzumab in Metastatic Colorectal Cancer - - Findings Presented Today at the European Society for Medical Oncology (ESMO) 2019 Congress - Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that initial data were presented from the si...

Got this from SGEN - Initial Results from MOUNTAINEER Trial Show Antitumor Activity of Tucatinib Combination in HER2-Positive Metastatic Colorectal Cancer
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SGEN News